



FOR IMMEDIATE RELEASE

Media contact: Shelley Parnell
parnell@visiongate3d.com
480.703.9268

VisionGate Lung Cancer 3D Cellular Imaging Research to be Featured as a Late-Breaking Abstract at the AACR Annual Meeting 2018

SEATTLE, WA (April 12, 2018) – VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce that new lung cancer 3D cellular imaging research findings will be presented at the upcoming 2018 American Association of Cancer Research (AACR) annual meeting in Chicago, Illinois from April 14-18, 2018.

The abstract presentation includes a breakthrough research study using the Company's Cell-CT™ platform 3D cellular imaging technology to detect subtle alterations in cellular and nuclear architecture in non-cancerous cells caused by the "field effect" that cancer cells exert on their microenvironment – known as Malignancy Associated Change (MAC).

"We are excited to present this important study at this year's AACR Annual Meeting," said Michael Meyer, VisionGate's Chief Technology Officer, "The acceptance of this abstract and its results represent significant progress that VisionGate continues to make in the pursuit of innovation in the early detection and treatment of cancer."

VisionGate, Inc. is pleased to be attending the AACR Annual Meeting in Chicago April 14-18 where the Company will be presenting late-breaking research:

Title: The Malignancy Associated Change Hypothesis Tested Through 3D Cellular Imaging

Presentation Number: Abstract #LB-175

Session: Late-Breaking Research: Epidemiology and Prevention

Date and Time: Monday, April 16, 2018, 1:00 p.m. – 5:00 p.m. CDT, Chicago

Location: Poster Section 44, Poster Board 18

Full session details and data presentation listings for AACR 2018 can be found at:

<http://www.abstractsonline.com/pp8/#!/4562>

VisionGate will also be engaging with potential biopharmaceutical collaborators and external experts throughout the meeting. To arrange for a meeting, please contact the Company by calling 602-368-6132, through our Linked In corporate account or our website at www.visiongate3d.com.

For more information on VisionGate, please visit www.visiongate3d.com.

###

About VisionGate, Inc.

VisionGate is a clinical stage oncology pharmaceutical and diagnostics company focused on the early detection and prevention of cancer. Our lead investigative pharmaceutical drug is oral iloprost, currently in clinical development for the treatment of pre-cancerous bronchial dysplasia and the prevention of lung cancer following a successful Phase 2 clinical trial. The LuCED® lung test will be the companion diagnostic for oral iloprost. VisionGate's proprietary LuCED lung test is a non-invasive liquid biopsy diagnostic test in development for detection of early-stage lung cancer, demonstrating exquisite sensitivity

and specificity in blinded clinical studies. This non-invasive sputum test is performed on the world's first automated 3D single cell imaging and analysis technology, the Cell-CT™ platform, named aptly because it is similar in principle to taking a computed tomography (CT) scan of individual cells, but using visible light without harmful radiation. With 176 issued patents in 13 countries, VisionGate expects to play a leading role in the battle against lung cancer - the world's number one cancer killer. VisionGate, Inc. is led by Dr. Alan Nelson, physicist, bioengineer, and serial entrepreneur who previously developed the world's first and only automated screening test to detect cervical cancer, marketed globally today as FocalPoint by Becton Dickinson. The LuCED lung test is a product in development and is not currently available commercially.

About the Cell-CT™ 3D Imaging Platform

The automated Cell-CT™ 3-Dimensional Single Cell Imaging and Analysis Platform is the enabling technology which produces high-resolution 3D images of individual cells using a technique called *optical computed tomography*. This 3D optical CT platform breaks new ground in the field of quantitative cell analysis by its unique ability to computationally reconstruct the true 3D internal structure of cells based on molecular optical absorption densities. The Cell-CT platform produces high-resolution 3D images of individual cells and measures hundreds of critical disease indicators in each cell. Together with advanced artificial intelligence (AI) algorithms, these produce accurate cell classifications that aid in the early detection of disease. Additionally, the Cell-CT platform has the potential to deliver molecular and genetic biosignatures of disease longitudinally to complement drug development in the biopharma services arena. Cells are not placed on slides, but rather, they are suspended in fluid (liquid biopsy) and injected through a micro-capillary tube that permits multiple viewing perspectives around 360°. The Cell-CT platform is a device under development and not currently cleared in the US.

Cautionary Note Regarding Forward-Looking Statements for VisionGate

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. These forward-looking statements are based on estimates, projections, beliefs and assumptions of the Company at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company's development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug and diagnostics development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice. VisionGate disclaims any intent or obligation to update these forward-looking statements. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.